Aztreonam–avibactam: The dynamic duo against multidrug‐resistant gram‐negative pathogens
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024-12 · 44 (12) · 927-938
DOI: 10.1002/phar.4629 ↗At a glance
Übersichtsarbeit in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, published online on 2024-11-27. Written by Mohammed Al Musawa and 5 co-authors. Institution: Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University…. Major MEDLINE topics: Anti-Bacterial Agents, Azabicyclo Compounds, Aztreonam, Drug Resistance, Multiple, Bacterial. Cited 68 times so far (Crossref); 63 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Antimicrobial resistance poses a significant public health challenge, particularly with the rise of gram‐negative hospital‐acquired infections resistant to carbapenems. Aztreonam–avibactam (ATM–AVI) is a promising new combination therapy designed to combat multidrug‐resistant (MDR) gram‐negative bacteria, including those producing metallo‐β‐lactamases (MBLs). Aztreonam, a monobactam antibiotic, is resistant to hydrolysis by MBLs but can be degraded by other β‐lactamases. Avibactam, a novel non‐β‐lactam β‐lactamase inhibitor, effectively neutralizes extended‐spectrum β‐lactamases (ESBLs) and AmpC β‐lactamases, restoring aztreonam's efficacy against resistant pathogens. This review covers the chemistry, mechanisms of action, spectrum of activity, pharmacokinetics, pharmacodynamics, and clinical efficacy of ATM–AVI. ATM–AVI combination has shown efficacy against a wide range of resistant Enterobacterales and other gram‐negative bacteria in both in vitro and clinical studies. Pharmacokinetic and pharmacodynamic analyses demonstrate that ATM–AVI maintains effective drug concentrations in the body, with dose adjustments recommended for patients with renal impairment. Clinical trials, including the REVISIT and ASSEMBLE studies, have demonstrated the safety and efficacy of ATM–AVI in treating complicated intra‐abdominal infections (cIAI), urinary tract infections (UTIs), and hospital‐acquired pneumonia (HAP) caused by MDR gram‐negative pathogens. The European Medicines Agency (EMA) has approved ATM–AVI for these indications, and further research is ongoing to optimize dosing regimens and expand its clinical use. This combination represents a critical advancement in the fight against antimicrobial resistance, offering a new therapeutic option for treating severe infections caused by MDR gram‐negative, including MBL‐producing, bacteria.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
- John D. Dingell VA Medical Center, Detroit, Michigan, USA.
- Department of Pharmacy Services, Detroit Receiving Hospital, Detroit Medical Center, Detroit, Michigan, USA.
- Division of Infectious Diseases, School of Medicine, Wayne State University, Detroit, Michigan, USA.
ORCID profiles: Mohammed Al Musawa, Callan R Bleick, Shelbye R Herbin, Kaylee E Caniff, Sean R Van Helden, Michael J Rybak
Cite
APA
Al Musawa, M., Bleick, C. R., Herbin, S. R., Caniff, K. E., Van Helden, S. R., & Rybak, M. J. (2024). Aztreonam–avibactam: The dynamic duo against multidrug‐resistant gram‐negative pathogens. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 44(12), 927-938. https://doi.org/10.1002/phar.4629
Vancouver
Al Musawa M, Bleick CR, Herbin SR, Caniff KE, Van Helden SR, Rybak MJ. Aztreonam–avibactam: The dynamic duo against multidrug‐resistant gram‐negative pathogens. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024;44(12):927-938. doi:10.1002/phar.4629
BibTeX
@article{AlMusawa2024,
author = {Al Musawa, Mohammed and Bleick, Callan R and Herbin, Shelbye R and Caniff, Kaylee E and Van Helden, Sean R and Rybak, Michael J},
title = {Aztreonam–avibactam: The dynamic duo against multidrug‐resistant gram‐negative pathogens},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2024},
volume = {44},
number = {12},
pages = {927--938},
doi = {10.1002/phar.4629}
}
EUVIMED